99% Purity Lenalidomide Sample 191732-72-6 Pharmaceutical Intermediate with Reasonable Price

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: 98-99%
• Model NO.: MT-007
• Color: White to Yellow
• Sample: Small Quantities Available
• Testing: HPLC, Gc, Nmr
• Transport Package: Foil Bag, Cardboard Drum
• Specification: 10g, 20g, 50g, 100g, 500g
• Trademark: MT
• Origin: China
• HS Code: 2933990000
• Production Capacity: 50kgs /Month

Product Description

99% Purity Lenalidomide Sample 191732-72-6 Pharmaceutical Intermediate with Reasonable Price

Description 

Basic information Lenalidomide CAS NO. 191732-72-6:

 

Product Name	Lenalidomide
Synonyms	lenalidomide;3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;LenalidomideLenalidomide;1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione;CC-5013;Revlimi;Lenalidomide(other anti-cancers)
CAS	191732-72-6
MF	C13H13N3O3
MW	259.26062
EINECS	1308068-626-2
Product Categories	Molecular Targeted Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;Amines;Heterocycles;Inhibitor;CC-5013;Inhibitors;pharmaceutical intermediate

 

Chemical Properties Lenalidomide CAS NO. 191732-72-6:

 

Melting point	269-271°C
Risk Statements	20/21/22
Safety Statements	36/37
HazardClass	IRRITANT
storage temp.	-20°C Freezer

 

 Spec. Lenalidomide CAS NO. 191732-72-6:

Test Items	Specifications	Results
Appearance	White to light yellow crystalline powder	conforms
Water content	≤ 4.0%	0.021
Residuce on ignition	≤ 0.5%	0.0032
Residual Solvents	Methanol≤ 3000ppm	1400ppm
	Acetonitrile≤ 410ppm	not detected
	Carbon tetrachloride≤ 4ppm	not detected
	Tetrahydrofuran≤ 720ppm	250ppm
	Dimethylformamide	320ppm
	≤ 550ppm
Related Substance	Single Impurity≤1%	0.004
	Total Impurity≤1.5%	0.008
Assay	≥98.0%	0.996

Function 

• Lenalidomide is an anti-tumor drug developed by Celgene biopharmaceutical company. The chemical structure is similar to thalidomide, which has multiple functions such as anti-tumor, immune regulation and anti-angiogenesis.
• Lenalidomide inhibits the secretion of proinflammatory cytokines and increases the secretion of anti-inflammatory cytokines in peripheral blood monocytes.
• Lenalidomide can also inhibit the expression of cyclooxygenase 2(cox-2), but it has no effect on cox-1.
• Lenalidomide besides can be used to treat MDS and MM, for multiple myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized the degeneration amylum and with marrow unripe systemic bone marrow fibrosis disease have certain curative effect.
• Lenalidomide is currently the most effective drug to treat multiple myeloma.